Comparison between HPHC levels in THS 2.2 aerosol and cigarette smoke

17 March 2023

In 2012, the U.S. Food and Drug Administration (FDA) published a list of harmful and potentially harmful constituents (HPHCs) found in tobacco products and tobacco smoke, known as the FDA 93 list as it comprises 93 compounds or classes of compounds. This list covers toxicants linked to diseases such as cancer and cardiovascular disease, among others.

Also in 2012, the FDA published a guidance document for the tobacco industry for the reporting of HPHCs in tobacco smoke, which included 18 analytes to serve as a representative sample from among the FDA 93 list. These 18 analytes focus on smoke constituents for which testing and analytic methods are well established and widely available, and it included representatives of several different chemical classes. In our PMI-58 list of analytes, we include all 18 of those analytes in addition to recommended analytes from lists published by the World Health Organization and Health Canada.

Below, we’ve listed the levels of those HPHCs (with the exception of nicotine) measured in the smoke of a standard reference cigarette (3R4F) and the aerosols of two versions of our Tobacco Heating System (THS 2.2), the THS 2.2 Regular and the THS 2.2 Smooth Menthol. In all cases where a comparison could be made, we found that HPHC levels in the THS were lower compared to 3R4F, with an average reduction of more than 90.5% on a stick basis for THS 2.2 Regular and more than 91.0% on a stick basis for THS 2.2 Smooth Menthol.

The reductions in this table are fully in line with the one previously calculated using the PMI-58 list. The similarity of the results between the THS regular and THS menthol also show that the reduction in levels of HPHCs is related to the heat-not-burn principle and not impacted by the nature of the flavor system.

Here are the levels of HPHCs, as well as standard deviation (SD), for the THS 2.2 Regular and THS 2.2 Smooth Menthol, compared to 3R4F. The number of replicates for each analyte is 3. All analyses were conducted by Labstat International ULC (Kitchener, ON, Canada), an independent laboratory, according to their own methods and protocols. The standard Health Canada Intense smoking regime was applied to both the 3R4F and the THS.

Abbreviations:

AαC: 2-Amino-9H-pyrido[2,3-b]indole
CDD: Chlorodibenzo-p-dioxin
CDF: Chlorodibenzofuran
CO: Carbon monoxide
Glu-P-1: 2-Amino-6-methyldipyrido[1,2-a: 3',2'-d]imidazole
Glu-P-2: 2-Aminodipyrido[1,2-a: 3',2'-d]imidazole
IQ: 2-Amino-3-methylimidazo[4,5-f]quinoline
MeAαC: 2-Amino-3-methyl)-9H-pyrido[2,3-b]indole
NDEA: N-Nitrosodiethylamine
NDELA : N-Nitrosodiethanolamine
NDMA: N-Nitrosodimethylamine
NEMA: N-Nitrosomethylethylamine
NMOR: N-Nitrosomorpholine
NPIP: N-Nitrosopiperidine
NPYR: N-Nitrosopyrrolidine
PAHs: Polycyclic aromatic hydrocarbons
PhIP: 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine
Trp-P-1: 3-Amino-1,4-dimethyl-5H-pyrido[4,3-b]indole
Trp-P-2: 1-Methyl-3-amino-5H-pyrido[4,3-b]indole
TSNA: Tobacco-specific nitrosamines

The PMI-58 list of Harmful and Potentially Harmful Constituents

We routinely monitor the levels of the required constituents in standardized settings and we aim to reduce and, if possible, completely eliminate their formation in our smoke-free products.

PMI Presents to US FDA Advisory Committee

The presentation covers: THS heating technology, assessment results, perception & behavior data, plans to introduce THS in the U.S., and population health impact modeling.

Why the US FDA authorized THS to be marketed in US

Dr. Moira Gilchrist discusses several of the key reasons behind the U.S. FDA's decision to authorize the sale of the heated tobacco product.

reports-office-16x9.jpg

U.S. FDA Premarket tobacco products application

The assessment of the product submitted as a Premarket Tobacco Product Application to U.S. FDA.

fda-premarket.jpg

U.S. FDA Modified Risk Tobacco Product (MRTP) Application

The assessment of IQOS is described in our Modified Risk Tobacco Product (MRTP) applications to U.S. FDA.

PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.